Daewoong Pharma - Asset Resilience Ratio
Daewoong Pharma (069620) has an Asset Resilience Ratio of 0.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Daewoong Pharma to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Daewoong Pharma's Asset Resilience Ratio has changed over time. See 069620 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Daewoong Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Daewoong Pharma worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.36 Billion | 0.19% |
| Total Liquid Assets | ₩4.36 Billion | 0.19% |
Asset Resilience Insights
- Limited Liquidity: Daewoong Pharma maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Daewoong Pharma Industry Peers by Asset Resilience Ratio
Compare Daewoong Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Daewoong Pharma (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Daewoong Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.68% | ₩13.40 Billion ≈ $9.08 Million |
₩1.98 Trillion ≈ $1.34 Billion |
-0.99pp |
| 2023-12-31 | 1.67% | ₩26.18 Billion ≈ $17.74 Million |
₩1.57 Trillion ≈ $1.06 Billion |
-0.74pp |
| 2022-12-31 | 2.41% | ₩37.70 Billion ≈ $25.55 Million |
₩1.56 Trillion ≈ $1.06 Billion |
-4.50pp |
| 2021-12-31 | 6.91% | ₩97.83 Billion ≈ $66.30 Million |
₩1.42 Trillion ≈ $959.05 Million |
-0.76pp |
| 2020-12-31 | 7.67% | ₩104.82 Billion ≈ $71.04 Million |
₩1.37 Trillion ≈ $926.33 Million |
-0.18pp |
| 2019-12-31 | 7.85% | ₩97.74 Billion ≈ $66.23 Million |
₩1.25 Trillion ≈ $844.17 Million |
+2.28pp |
| 2018-12-31 | 5.57% | ₩67.25 Billion ≈ $45.57 Million |
₩1.21 Trillion ≈ $818.54 Million |
+0.96pp |
| 2017-12-31 | 4.61% | ₩55.96 Billion ≈ $37.92 Million |
₩1.21 Trillion ≈ $822.39 Million |
-2.60pp |
| 2016-12-31 | 7.21% | ₩82.56 Billion ≈ $55.95 Million |
₩1.14 Trillion ≈ $775.75 Million |
-2.54pp |
| 2015-12-31 | 9.76% | ₩92.16 Billion ≈ $62.45 Million |
₩944.53 Billion ≈ $640.09 Million |
-7.29pp |
| 2014-12-31 | 17.05% | ₩118.38 Billion ≈ $80.23 Million |
₩694.26 Billion ≈ $470.49 Million |
+10.42pp |
| 2013-12-31 | 6.63% | ₩38.37 Billion ≈ $26.00 Million |
₩579.01 Billion ≈ $392.39 Million |
+6.60pp |
| 2012-12-31 | 0.02% | ₩112.00 Million ≈ $75.90K |
₩482.34 Billion ≈ $326.88 Million |
-4.47pp |
| 2008-12-31 | 4.49% | ₩21.85 Billion ≈ $14.81 Million |
₩486.24 Billion ≈ $329.52 Million |
-0.15pp |
| 2007-12-31 | 4.64% | ₩18.23 Billion ≈ $12.35 Million |
₩392.81 Billion ≈ $266.20 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more